(0.29%) 5 114.69 points
(0.30%) 38 353 points
(0.34%) 15 982 points
(-0.94%) $83.06
(5.36%) $2.03
(0.32%) $2 354.70
(0.56%) $27.69
(4.33%) $962.00
(-0.26%) $0.932
(-0.45%) $10.97
(-0.58%) $0.796
(1.63%) $93.37
Live Chart Being Loaded With Signals
Cerecor Inc., a biopharmaceutical company, focuses on development and commercialization of treatments for rare pediatric and orphan diseases. It develop therapies for the treatment of inherited metabolic disorders, such as CERC-801 and CERC-802, which completed the phase I clinical trial; and CERC-803...
Stats | |
---|---|
本日の出来高 | 258 592 |
平均出来高 | 639 167 |
時価総額 | 38.63M |
EPS | $-0.180 ( 2021-08-02 ) |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -3.38 |
ATR14 | $0.168 (5.73%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2021-08-18 | Armistice Capital, Llc | Buy | 20 000 | Common Stock |
2021-08-16 | Armistice Capital, Llc | Buy | 30 000 | Common Stock |
2021-07-01 | Cola Michael F | Buy | 51 740 | Stock Option (Right to Buy) |
2021-06-30 | Bruhn Suzanne Louise | Buy | 3 465 | Stock Option (Right to Buy) |
2021-06-30 | Kaplan Gilla | Buy | 6 353 | Stock Option (Right to Buy) |
INSIDER POWER |
---|
0.00 |
Last 95 transactions |
Buy: 9 414 351 | Sell: 408 195 |
ボリューム 相関
Cerecor Inc 相関
10 最も負の相関 | |
---|---|
RMRM | -0.941 |
DBX | -0.92 |
PTC | -0.911 |
PCT | -0.898 |
DUSA | -0.894 |
DWUS | -0.89 |
DEMZ | -0.889 |
PSET | -0.888 |
EXPI | -0.885 |
SAMG | -0.883 |
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Cerecor Inc 相関 - 通貨/商品
Financial Reports:
No articles found.
Cerecor Inc
Cerecor Inc., a biopharmaceutical company, focuses on development and commercialization of treatments for rare pediatric and orphan diseases. It develop therapies for the treatment of inherited metabolic disorders, such as CERC-801 and CERC-802, which completed the phase I clinical trial; and CERC-803. The company is also involved in the developing of CERC-007, an anti-IL-18 monoclonal antibody for the treatment of autoimmune inflammatory diseases, such as adult onset stills disease and multiple myeloma; CERC-006, a dual mTOR inhibitor to treat complex lymphatic malformations; and CERC-002, an anti-LIGHT monoclonal antibody for the treatment of Pediatric-onset Crohn's diseases. In addition, it develops CERC-913, a protide nucleotide for the treatment of mitochondrial disorder; CERC-005, a monoclonal antibody to treat rare auto-inflammatory diseases; CERC-301 for the treatment of symptomatic Orthostatic Hypotension; and CERC-406 for the treatment of Parkinson's disease. Further, the company offers Millipred, an oral prednisolone for the treatment of inflammatory conditions, such as arthritis, blood disorders, immune system disorders, skin and eye conditions, respiratory disorders, cancer, and severe allergies. The company was formerly known as Ceregen Corporation and changed its name to Cerecor Inc. in March 2011. Cerecor Inc. was founded in 2011 and is headquartered in Rockville, Maryland.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。